You do not currently have access to this content.

Cancer Res (2022) 82 (12_Supplement): 3595. Combination treatment with RMC-6291 and SHP2 or SOS1 inhibitors was well tolerated in preclinical models and further increased anti-tumor activity, likely ...

Background: KRAS is a key mediator of the RAS/MAPK signaling cascade and promotes cellular growth and proliferation. It is the most frequently mutated oncogene in cancer, and KRAS G12C mutations occur ...

Background. HER2 testing in tissue biopsies is extensively performed in breast cancer (BC) patients. However, tissue biopsy is invasive and repeated examination is impractical. Additionally, lack of ...

Abstract. A key barrier to effective immunotherapy for cancer is the immunosuppressive tumor microenvironment (TME) characterized by infiltrating regulatory T cells (Tregs) and myeloid-derived ...

Abstract:. Researchers utilized a two-vector system, consisting of an enveloped delivery vehicle and an adeno-associated virus to deliver CRISPR tools and a large DNA payload, to achieve stable and ...

Although T cell–based therapies have shown great promise for treatment of hematologic malignancies, many barriers limit their success in solid tumor types. One such limitation is the scarcity of ...

De novo pyrimidine synthesis is a universal requirement for cancer cell proliferation; however, targeting this pathway results in toxicity to all dividing cells. The rate limiting conversion of UTP to ...

Abstract. Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate (ADC) directed against CD30. It consists of an anti-CD30 monoclonal antibody conjugated to monomethyl auristatin E (MMAE), a ...

Cancer Epidemiol Biomarkers Prev (2009) 18 (6): 1740–1745. The U.S. active-duty military population may differ from the U.S. general population in its exposure to cancer risk factors and access to ...